Record quarterly sales surpassed $1 billion, with all segments growing and Pharma leading. Margins declined due to product mix and operational factors, but strong demand and innovation support a positive outlook. Q3 adjusted EPS is guided at $1.45–$1.53.Original document: AptarGroup, Inc. [ATR] SEC…
Record quarterly sales surpassed $1 billion, with all segments growing and Pharma leading. Margins declined due to product mix and operational factors, but strong demand and innovation support a positive outlook. Q3 adjusted EPS is guided at $1.45–$1.53.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
